Skip to main content

Table 5 Sensitivity analysis, with travel region as main parameter affecting the results.

From: Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea

 

Provider perspective

Societal perspective

Benefit-Cost

 
 

Net present value (€)

Net present value (€)

ratio

Δ

Base case

-30,958.12

79,280.45

1.39

 

Region of travel

    

Africa

-31,036.87

75,474.24

1.32

↓ 4.8%

C-S. America

-31,219.34

48,944.96

0.86

↓ 38.3%

India and SE. Asia

-30,809.61

88,856.44

1.55

↑ 12.1%